23:37 , Nov 30, 2017 |  BC Week In Review  |  Company News

Catalyst, Mosaic partner to develop anti-C3 proteases for dry AMD

Catalyst Biosciences Inc. (NASDAQ:CBIO) partnered with Mosaic Biosciences Inc. (Boulder, Colo.) to develop Catalyst’s preclinical anti-complement 3 (C3) proteases, including CB 2782, to treat dry age-related macular degeneration (AMD) and other inflammatory and retinal disorders....
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Catalyst Biosciences hematology news

Catalyst will reduce headcount by 10 (50%) to about 10 to focus resources on its hemostasis programs, primarily CB 813d and CB 2679d ( ISU 304). The company said it will continue to...